Hederagenin抑制类风湿关节炎中成纤维细胞样滑膜细胞的增殖、血管生成和炎症

IF 0.6 4区医学 Q4 PHARMACOLOGY & PHARMACY

Tropical Journal of Pharmaceutical Research Pub Date : 2023-11-06 DOI:10.4314/tjpr.v22i10.4

Ping Wang, Junli Yang, Xiaomeng Zhang

{"title":"Hederagenin抑制类风湿关节炎中成纤维细胞样滑膜细胞的增殖、血管生成和炎症","authors":"Ping Wang, Junli Yang, Xiaomeng Zhang","doi":"10.4314/tjpr.v22i10.4","DOIUrl":null,"url":null,"abstract":"Purpose: To determine the effect of Hederagenin (Hed) on rheumatoid arthritis (RA) in a cell model, and to elucidate the mechanism of action of Hed. Methods: MTT, EDU, and Immunoblot assays were used to determine the effects of Hed on the viability of fibroblast-like synovial cells, while the effects of Hed on inflammation were examined by enzymelinked immunosorbent assay (ELISA) and immunoblot assay. The influence of Hed on cell motility angiogenesis was evaluated by Transwell and tube formation assays, while immunoblot analysis was used to determine the mechanism of action of Hed. Results: Hed inhibited the viability of RA-FLS cells and suppressed the inflammation of RA-FLS cells (p < 0.05). Furthermore, Hed suppressed the migration and angiogenesis of RA-FLSl cells, as well as regulated MAPK pathway (p < 0.05). Conclusion: Hed inhibits the proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in RA by regulating MAPK pathway. Therefore, Hed is a drug for the treatment of RA, However, in vivo studies to validate these findings are recommended","PeriodicalId":23347,"journal":{"name":"Tropical Journal of Pharmaceutical Research","volume":"91 6","pages":"0"},"PeriodicalIF":0.6000,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hederagenin inhibits proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in rheumatoid arthritis\",\"authors\":\"Ping Wang, Junli Yang, Xiaomeng Zhang\",\"doi\":\"10.4314/tjpr.v22i10.4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Purpose: To determine the effect of Hederagenin (Hed) on rheumatoid arthritis (RA) in a cell model, and to elucidate the mechanism of action of Hed. Methods: MTT, EDU, and Immunoblot assays were used to determine the effects of Hed on the viability of fibroblast-like synovial cells, while the effects of Hed on inflammation were examined by enzymelinked immunosorbent assay (ELISA) and immunoblot assay. The influence of Hed on cell motility angiogenesis was evaluated by Transwell and tube formation assays, while immunoblot analysis was used to determine the mechanism of action of Hed. Results: Hed inhibited the viability of RA-FLS cells and suppressed the inflammation of RA-FLS cells (p < 0.05). Furthermore, Hed suppressed the migration and angiogenesis of RA-FLSl cells, as well as regulated MAPK pathway (p < 0.05). Conclusion: Hed inhibits the proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in RA by regulating MAPK pathway. Therefore, Hed is a drug for the treatment of RA, However, in vivo studies to validate these findings are recommended\",\"PeriodicalId\":23347,\"journal\":{\"name\":\"Tropical Journal of Pharmaceutical Research\",\"volume\":\"91 6\",\"pages\":\"0\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tropical Journal of Pharmaceutical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4314/tjpr.v22i10.4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tropical Journal of Pharmaceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4314/tjpr.v22i10.4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的:建立细胞模型，观察Hederagenin (Hed)对类风湿关节炎(RA)的作用，并探讨其作用机制。方法:采用MTT法、EDU法和免疫印迹法检测Hed对成纤维细胞样滑膜细胞活力的影响，采用酶联免疫吸附法(ELISA)和免疫印迹法检测Hed对炎症的影响。采用Transwell法和成管法观察Hed对血管生成细胞运动的影响，免疫印迹法研究Hed的作用机制。结果:Hed抑制RA-FLS细胞活力，抑制RA-FLS细胞炎症反应(p <0.05)。此外，Hed抑制RA-FLSl细胞的迁移和血管生成，并调节MAPK通路(p <0.05)强生# x0D;结论:Hed通过调控MAPK通路抑制RA成纤维细胞样滑膜细胞的增殖、血管生成和炎症。因此，Hed是一种治疗类风湿性关节炎的药物，然而，建议进行体内研究来验证这些发现

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Hederagenin inhibits proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in rheumatoid arthritis

Purpose: To determine the effect of Hederagenin (Hed) on rheumatoid arthritis (RA) in a cell model, and to elucidate the mechanism of action of Hed. Methods: MTT, EDU, and Immunoblot assays were used to determine the effects of Hed on the viability of fibroblast-like synovial cells, while the effects of Hed on inflammation were examined by enzymelinked immunosorbent assay (ELISA) and immunoblot assay. The influence of Hed on cell motility angiogenesis was evaluated by Transwell and tube formation assays, while immunoblot analysis was used to determine the mechanism of action of Hed. Results: Hed inhibited the viability of RA-FLS cells and suppressed the inflammation of RA-FLS cells (p < 0.05). Furthermore, Hed suppressed the migration and angiogenesis of RA-FLSl cells, as well as regulated MAPK pathway (p < 0.05). Conclusion: Hed inhibits the proliferation, angiogenesis and inflammation of fibroblast-like synovial cells in RA by regulating MAPK pathway. Therefore, Hed is a drug for the treatment of RA, However, in vivo studies to validate these findings are recommended

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Tropical Journal of Pharmaceutical Research 医学-药学

CiteScore

1.00

自引率

33.30%

发文量

490

审稿时长

4-8 weeks

期刊介绍： We seek to encourage pharmaceutical and allied research of tropical and international relevance and to foster multidisciplinary research and collaboration among scientists, the pharmaceutical industry and the healthcare professionals. We publish articles in pharmaceutical sciences and related disciplines (including biotechnology, cell and molecular biology, drug utilization including adverse drug events, medical and other life sciences, and related engineering fields). Although primarily devoted to original research papers, we welcome reviews on current topics of special interest and relevance.